

Exhibit 6

In The Matter Of:

ARIA DIAGNOSTICS, INC.

v.

SEQUENOM, INC.

TATMAN, Ph.D., DERECK A. S. - Vol. 1
April 24, 2012

MERRILL CORPORATION

Legalink, Inc.

20750 Ventura Boulevard
Suite 205
Woodland Hills, CA 91364
Phone: 818.593.2300
Fax: 818.593.2301

DERECK A. S. TATMAN, Ph.D. - 4/24/2012

UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF CALIFORNIA

--oOo--

ARIA DIAGNOSTICS, INC.,)	
)	
Plaintiff,)	
)	Case No.
v.)	3:11-cv-06391-SI
)	
SEQUENOM, INC.,)	
)	
Defendant/)	
Counterclaim-Plaintiff.))	
)	
v.)	
)	
ARIA DIAGNOSTICS, INC.,)	
)	
Counterclaim-Defendant,)	
)	
and)	
)	
ISIS INNOVATION LIMITED,)	
)	
Nominal Counterclaim-)	
Defendant.)	
_____)	

CONFIDENTIAL - OUTSIDE ATTORNEYS' EYES ONLY

VIDEOTAPED DEPOSITION OF
DERECK A. S. TATMAN, Ph.D.

Tuesday, April 24, 2012

REPORTED BY: SHERRI STARR, CRR, CSR 10245

1	novelty of the invention," what do you mean by "the	09:50:36
2	invention"?	09:50:39
3	MR. ROOT: Objection. Lacks foundation.	09:50:43
4	Calls for a legal conclusion.	09:50:44
5	THE WITNESS: The general ability to	09:50:47
6	detect and analyze extracellular fetal nucleic acids	09:50:52
7	in maternal circulation.	09:50:59
8	MS. GLASSER: Q. Now, what was it that	09:51:09
9	Dr. Lo or Dr. Wainscoat discovered that provided	09:51:10
10	this ability to detect and analyze the extracellular	09:51:16
11	fetal nucleic acids?	09:51:21
12	MR. ROOT: Objection. Lacks foundation.	09:51:23
13	Calls for speculation.	09:51:24
14	THE WITNESS: Can you repeat the question,	09:51:32
15	please?	09:51:33
16	MS. GLASSER: Would you mind reading it	09:51:34
17	back?	09:51:36
18	(The record was read as	09:51:46
19	follows:	09:51:46
20	"Question: Now, what was it	09:51:46
21	that Dr. Lo or Dr. Wainscoat	09:51:46
22	discovered that provided this	09:51:46
23	ability to detect and analyze	09:51:46
24	the extracellular fetal	09:51:46
25	nucleic acids?")	09:51:46

1	MR. ROOT: Same objections.	09:51:47
2	THE WITNESS: They discovered the presence	09:51:51
3	of such fetal nucleic acids in maternal circulation	09:51:53
4	and the ability to detect those using standard	09:51:58
5	technologies of the time.	09:52:02
6	MS. GLASSER: Q. And what were the	09:52:05
7	standard technologies of the time?	09:52:06
8	A. PCR-based methodologies.	09:52:12
9	Q. What does PCR do?	09:52:15
10	MR. ROOT: Objection. Lacks foundation.	09:52:18
11	THE WITNESS: PCR is the ability to	09:52:22
12	amplify and detect nucleic acids in solution.	09:52:24
13	MS. GLASSER: Q. And how long had that	09:52:36
14	been known in the art in the industry?	09:52:38
15	MR. ROOT: Objection. Lacks foundation.	09:52:43
16	THE WITNESS: I don't recall. Whenever	09:52:48
17	Kary Mullis reduced it to practice.	09:52:55
18	MS. GLASSER: Q. How does Sequenom	09:52:58
19	amplify in its MaterniT21 product?	09:53:12
20	MR. ROOT: Objection. Lacks foundation.	09:53:18
21	THE WITNESS: I don't know the specifics	09:53:23
22	of the amplification process within our product.	09:53:24
23	MS. GLASSER: Q. Do you know it in	09:53:28
24	general terms?	09:53:31
25	MR. ROOT: Objection. Lacks foundation.	09:53:31

1	THE WITNESS: In general, we amplify prior	09:53:37
2	to loading onto sequencers.	09:53:39
3	MS. GLASSER: Q. Is there a particular	09:53:45
4	method of amplification that you use?	09:53:46
5	MR. ROOT: Objection. Lacks foundation.	09:53:50
6	THE WITNESS: Well, we run this in the	09:53:54
7	clinical lab, so it's a very specific method and	09:53:55
8	protocol. I don't know what the specific	09:53:58
9	amplification procedure is as part of that process.	09:54:00
10	MS. GLASSER: Q. Is it a PCR-based	09:54:04
11	methodology?	09:54:07
12	MR. ROOT: Objection. Lacks foundation.	09:54:08
13	THE WITNESS: It is PCR-based.	09:54:11
14	MS. GLASSER: Q. How long did it take	09:54:18
15	Sequenom to develop its PCR-based amplification	09:54:19
16	methodology?	09:54:23
17	MR. ROOT: Objection. Lacks foundation.	09:54:25
18	Vague and ambiguous.	09:54:28
19	THE WITNESS: For the MaterniT21 test?	09:54:30
20	MS. GLASSER: Q. Yes.	09:54:33
21	MR. ROOT: Same objections.	09:54:36
22	THE WITNESS: I don't know how much	09:54:50
23	research effort was expended on that.	09:54:53
24	MS. GLASSER: Q. Is more than a couple	09:54:59
25	days, less than ten years accurate range?	09:55:03

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DECLARATION

I hereby declare I am the deponent in the within matter and that I have read the foregoing deposition and know the contents thereof.

I declare under penalties of perjury under the laws of the United States that the foregoing is true and correct.

This declaration is executed this ____ day of_____, 2012, at _____, California.

Dereck A. S. Tatman, Ph.D.

DERECK A. S. TATMAN, Ph.D. - 4/24/2012

1 CERTIFICATE OF REPORTER


2 I, SHERRI STARR, a Certified Shorthand
3 Reporter, hereby certify that the witness in the
4 foregoing deposition was by me duly sworn to tell
5 the truth, the whole truth, and nothing but the
6 truth in the within-entitled cause;

7 That said deposition was taken in
8 shorthand by me, a disinterested person, at the time
9 and place therein stated, and that the testimony of
10 the said witness was thereafter reduced to
11 typewriting, by computer, under my direction and
12 supervision;

13 That before completion of the deposition,
14 review of the transcript [] was [X] was not
15 requested. If requested, any changes made by the
16 deponent (and provided to the reporter) during the
17 period allowed are appended hereto.

18 I further certify that I am not of counsel
19 or attorney for either or any of the parties to the
20 said deposition, nor in any way interested in the
21 event of this cause, and that I am not related to
22 any of the parties thereto.

23 Dated: April 25, 2012.

24 
25 SHERRI STARR, CSR No. 10245